ENHERTU approved in China as the first and only HER2 directed ADC for the second-Line...

Daiichi Sankyo Korea and AstraZeneca Korea receive approval for Enhertu for patients with HER2 low-...

Lilly’s sofetabart mipitecan receives U.S. FDA’s Breakthrough Therapy designation for the treatment of certain patients...

Sichuan Baili Tianheng Pharmaceutical’s BL-B01D1 marketing application (NDA) has been formally accepted by China’s National...

Avacta announces U.S. Food and Drug Administration clearance of the Investigational New Drug (IND) application...

Ellipses in-licenses first-in-class B7H3 Antibody Drug Conjugate from China